BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Nexvet Biopharma To Present At The Cowen and Company 34th Annual Health Care Conference On March 5, 2014


2/18/2014 11:06:18 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MELBOURNE, AUSTRALIA--(Marketwired - February 18, 2014) - Nexvet Biopharma, a leading veterinary biologic drug developer, today announced that Dr Mark Heffernan, Nexvet's Chief Executive Officer, is scheduled to present at the 34th Annual Cowen Health Care Conference in Boston on Wednesday, March 5, 2014 at 11:30 AM EST.

Dr Heffernan will provide an overview of Nexvet's pioneering developments in the field of 100% species-specific monoclonal antibody therapies for chronic conditions in pets (companion animals).

About Nexvet (www.nexvet.com)
Nexvet Biopharma is pioneering the field of monoclonal antibody therapies for companion animals (e.g. dogs and cats) using its proprietary PETisation™ platform technology, which uniquely produces therapies 100% customised to target species. The Nexvet portfolio focuses on areas of greatest unmet medical need such as chronic pain and inflammatory diseases, in addition to a significant pipeline of medically important products.

The area of biologics has become a massive growth area in human medicine, responsible for many of the most successful drugs on the market due to their clinical effectiveness, specificity and excellent side-effect profiles. Nexvet's team have international track records in the development of both human biologics and veterinary drugs, and are committed to developing biologics to drive innovation in the $20 billion global veterinary pharmaceuticals market. Nexvet is a privately held company based in Melbourne (Australia) with global operations, partners and investors.


Further information:

Investors
Mark Heffernan
Chief Executive Officer
Nexvet
+61 447 155 542
mark.heffernan@nexvet.com

Investors (US)
Candice Knoll
Blueprint Life Science Group
+1 415 375.3340 Ext. 105
cknoll@bplifescience.com

Media
Tom Donovan
Director of Communications
Nexvet
+61 422 557 107
tom.donovan@nexvet.com



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES